20240208171546.png)
James E. Rothman, PhD, a cell biologist whose career has focused on elucidating the underlying mechanisms of transport within cells, is a winner of the 2002 Albert Lasker Award for Basic Research.
A newly-identified genetic marker increases the risk for colorectal cancer approximately three-fold in individuals born with this mutation, according to a study.
Structural biologists at Memorial Sloan-Kettering Cancer Center (MSKCC) have discovered the function of the protein BRCA2. Mutations in the BRCA2 gene have been linked to hereditary breast and ovarian cancers.
Scientists have discovered a drug that prevents sterility in female mice after exposure to ionizing radiation. Additional findings suggest that this is accomplished without yielding genetic damage in the offspring of the irradiated mothers.
While it is true that detecting cancer at its earliest stages offers patients the best chance for cure, preventing it altogether is ideal. New evidence shows that surgery may be the most effective way to prevent breast and ovarian cancers in women who are most likely to develop these diseases.
Decades of research into the cell's molecular mechanics have produced a promising arsenal of drugs that selectively attack cancer cells and leave the surrounding normal tissue relatively untouched.
Reviewing the data from cancer outcome studies published over the past thirty-five years, a team of researchers led by scientists at Memorial Sloan-Kettering Cancer Center found that when black and white cancer patients received equal treatment, i.e. comparable care at a similar stage of disease, blacks still had a slight survival disadvantage.
Researchers at Memorial Sloan-Kettering Cancer Center have now provided strong evidence that breast and ovarian cancers can be detected at early stage in women at the highest hereditary risk.
In a development that holds promise for advancing the treatment of patients with sarcoma, researchers at Memorial Sloan-Kettering Cancer Center have developed a new prognostic tool that is more accurate than any previously available for this disease.
Representatives of approximately 100 national organizations will gather in Harlem January 3rd and 4th to discuss the medical, social, and spiritual supports needed to care for seriously ill and dying patients.
Research published in this weekÃs issue of Nature describes the molecular structure of two cancer-related proteins binding to one another. Scientists identified the biochemical and signaling properties of these molecules using a process called X-ray crystallography.
Harold Varmus, President of Memorial Sloan-Kettering Cancer Center, today announced the appointments of Robert E. Wittes as Physician-in-Chief of Memorial Hospital, and Thomas J. Kelly as Chairman of the Sloan-Kettering Institute.
Researchers at Memorial Sloan-Kettering Cancer Center have developed a molecular nanogenerator that releases a cascade of atomic fragments known as alpha particles on the inside of cancer cells.
Smokers who undergo low-dose helical computed tomographic scanning for lung cancer were motivated to quit smoking, according to a study conducted by researchers at Memorial Sloan-Kettering Cancer Center, and colleagues at Weill Medical College of Cornell University, and the Hospital for Special Surgery.
Recipients of the first Paul Marks Prize for Cancer Research, a unique $125,000 award to be shared by young investigators for major accomplishments in cancer research, have been named.
Following are highlights from research presented by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) during this week's annual meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO).
Researchers at Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University have discovered that tumor angiogenesis occurs when precursor cells from the bone marrow are mobilized and recruited by VEGF (vascular endothelial growth factor) stem cells to the tumor blood vessels.
Researchers at Memorial Sloan-Kettering Cancer Center have pioneered the use of computerized devices to help patients and their physicians decide among the major treatment choices for early stage prostate cancer. Such tools, called nomograms, have been developed to predict outcomes for surgery and radiation therapy, and now, brachytherapy (radioactive seed implantations) for early stage prostate cancer.
Radiologists at Memorial-Sloan Kettering Cancer Center are using computer-aided detection to second-read mammograms at the Center's Breast Examination Center of Harlem. The technology uses a computer to scan mammograms for abnormalities and may improve early detection of breast cancer with screening mammography by almost 20 percent.
Patients with lung cancer live longer if they have surgery at hospitals with experience, according to a study conducted by researchers at Memorial Sloan-Kettering Cancer Center.
Damage to the gastrointestinal tract, lung, and brain has long been the dose-limiting factor for chemotherapy and radiation therapy. But until now scientists did not know which cells targeted within those organs were responsible for the lethal responses.
The use of potentially curative chemotherapy following surgery for stage III colon cancer declines precipitously with patients' advancing age. The likelihood of a patient being offered this treatment option, shown in previous studies to reduce the risk of cancer recurrence and mortality by 30 percent, declined as their age at diagnosis increased.
A new study indicates that prostate cancer patients who have their prostate removed today have a better prognosis than patients who underwent the procedure ten years ago.
A new drug for the treatment of advanced-stage colorectal cancer can shrink tumors in some patients who have developed resistance to other chemotherapy agents.
Researchers are one step closer to the performance of therapeutic cloning in mice, with an eye not toward developing another mouse, but generating an unlimited source of genetically matched therapeutic dopamine cells. The technique may have implications for Parkinson's disease research.
Nominations are now being sought for the first Paul Marks Prizes for Cancer Research. The prizes will recognize significant discoveries made by outstanding investigators up to the age of 45 at the time of the award.
Researchers at Memorial Sloan-Kettering Cancer Center report that inactivation of just one copy of a gene called PTEN and both copies of a gene called p27 that leads to prostate cancer in mice 100 percent of the time. (Nature Genetics, 2-01)
What makes one patient's cancer more aggressive than another? Why does a patient's cancer develop resistance to a previously effective chemotherapy drug? A genetic mutation of the MAD2 protein may provide the answer to both of these questions.
A case-control study of 891 people who regularly used a cellular phone showed no statistical association between the amount of cell phone usage and the likelihood of developing brain cancer. (JAMA, 12-20-00)
Hospital experience is one of many important factors patients must consider when deciding where to have their surgery. New evidence published this week offers information that could aid patients in making that challenging decision. (JAMA)
Understanding why a terminally-ill patient wishes to die has become a focus for improving end of life care as well as a crucial part of the physician-assisted suicide debate.
The Cancer Information Service of New York was recently awarded one of four grants totaling $932,000 from the National Cancer Institute to improve awareness of and access to Internet-based cancer information in minority communities throughout the country.
Memorial Sloan-Kettering Cancer Center today launched a lay language database of high priority trials for its web site.
Patients with clinically localized prostate cancer have a better chance of beating the disease with higher doses of radiation, which can be safely and precisely delivered to the tumor with few side effects using three-dimensional conformal radiation therapy.
Doctors at Memorial Sloan-Kettering Cancer Center are developing new ways to more effectively treat lung cancer with radiation therapy by using enhanced imaging to better define tumors during treatment planning, and delivering higher doses with fewer side effects.
Women taking tamoxifen to prevent breast cancer receive no benefit from routine screening for endometrial cancer, a known risk associated with the drug. (Journal of Clinical Oncology, 10-15-00)
"Knocking out" a particular gene protects the ovaries of mice from damage, researchers at Memorial Sloan-Kettering Cancer Center, along with colleagues from Massachusetts General Hospital and other institutions, have discovered. (Nature Medicine, 10-00)
A new prognostic tool, developed at Memorial Sloan-Kettering Cancer Center, could aid physicians and patients in decision making regarding treatment options for early stage prostate cancer and in identifying those patients who are at high risk of recurrence following radiation therapy. (Journal of Clinical Oncology, 9-28-00)
Researchers at Memorial Sloan-Kettering Cancer Center report the development of a new chemotherapy regimen for first line treatment for patients with metastatic colorectal cancer. (New England Journal of Medicine, 9-28-00)
A scientific award has been established to honor Dr. Paul A. Marks on the occasion of his retirement as President of Memorial Sloan-Kettering Cancer Center.
A treatment combining traditional chemotherapy with medication delivered through a surgically implanted pump has been found to increase life expectancy in patients with advanced colorectal cancer that has spread to the liver, reports an oncologist at Memorial Sloan-Kettering Cancer Center.
Memorial Sloan-Kettering Cancer Center researchers have shown that a new combination treatment increases the number of patients with non-Hodgkin's lymphoma (NHL) who can receive potentially curative bone marrow transplantation.
A genetic mutation may account for up to nine percent of the colon cancer cases diagnosed in the United States, report scientists at Memorial Sloan-Kettering Cancer Center and other research centers in the November 15 issue of Cancer Research.
Research conducted by Memorial Sloan-Kettering Cancer Center investigators sheds new light on why existing therapies don't stop the prostate cancer from returning and was published in the November 3rd issue of the Journal of the National Cancer Institute.
Dr. Harold E. Varmus, Director of the National Institutes of Health and co-recipient of the 1989 Nobel Prize for Physiology or Medicine, will be the next President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center.
Although it has been known that a mutation in both copies of the PTEN tumor suppressor gene impairs a cell's ability to program its death, researchers have found that losing function of only one of the pair is enough to disrupt this vital signaling mechanism.
Researchers at Memorial Sloan-Kettering Cancer Center have found that cancer tumors consume large amounts of vitamin C, they reported in the September 15 issue of Cancer Research.
Memorial Sloan-Kettering Cancer Center scientists have achieved a major milestone: the first-ever molecular "snapshot" of a new drug interacting with its cellular target.
A new standard for cancer care and comfort has been established with the opening of Memorial Sloan-Kettering Cancer Center's Laurence S. Rockefeller Outpatient Pavilion.
Memorial Sloan-Kettering's new Laurence S. Rockefeller Outpatient Pavilion will house the country's first fully computerized photography system to follow patients at risk for melanoma,a deadly skin cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right